SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.08+0.9%Dec 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who started this subject6/28/2001 4:46:20 PM
From: Mark Bong   of 52153
 
AMGN favorable comments on PRCS drug Plenasis.

Here is a glimmer of light at the end of the FDA tunnel. Breadth of labeling will surely be an important issue here.

"The FDA has held up approval of Plenaxis. But (CEO Kevin)Sharer says that's part of a continuing discussion with regulators on how the drug should best be used, a question of labeling and not effectiveness".

siliconvalley.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News